Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns.

Date publication

avril 2024

Journal

JAMA network open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr HOTTON Judicaël

Tous les auteurs :
Gougis P, Hamy AS, Jochum F, Bihan K, Carbonnel M, Salem JE, Dumas E, Kabirian R, Grandal B, Barraud S, Coussy F, Hotton J, Savarino R, Marabelle A, Cadranel J, Spano JP, Laas E, Reyal F, Abbar B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38630478

Résumé

With the widespread use of immune checkpoint inhibitors (ICIs), concerns about their pregnancy outcomes through maternal exposure have emerged, and clinical comparative data are lacking.

Mots clés

Infant, Newborn, Pregnancy, Humans, Female, Adult, Cohort Studies, Immune Checkpoint Inhibitors, adverse effects, Premature Birth, Abortion, Spontaneous, Hypothyroidism, Neoplasms

Référence

JAMA Netw Open. 2024 04 1;7(4):e245625